| Warning:  Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
 Deprecated:  str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
  
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 
  free 
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
  free 
  free 
   English Wikipedia
 
 Nephropedia Template TP (
 
 Twit Text
 
 
 DeepDyve
 Pubget Overpricing
 | lüll   
 
 Targeting selectins and selectin ligands in inflammation and cancer Barthel SR; Gavino JD; Descheny L; Dimitroff CJExpert Opin Ther Targets  2007[Nov]; 11 (11): 1473-91Inflammation and cancer metastasis are associated with extravasation of  leukocytes or tumor cells from blood into tissue. Such movement is believed to  follow a coordinated and sequential molecular cascade initiated, in part, by the  three members of the selectin family of carbohydrate-binding proteins: E-selectin  (CD62E), L-selectin (CD62L) and P-selectin (CD62P). E-selectin is particularly  noteworthy in disease by virtue of its expression on activated endothelium and on  bone-skin microvascular linings and for its role in cell rolling, cell signaling  and chemotaxis. E-selectin, along with L- or P-selectin, mediates cell tethering  and rolling interactions through the recognition of sialo-fucosylated Lewis  carbohydrates expressed on structurally diverse protein-lipid ligands on  circulating leukocytes or tumor cells. Major advances in understanding the role  of E-selectin in inflammation and cancer have been advanced by experiments  assaying E-selectin-mediated rolling of leukocytes and tumor cells under  hydrodynamic shear flow, by clinical models of E-selectin-dependent inflammation,  by mice deficient in E-selectin and by mice deficient in glycosyltransferases  that regulate the binding activity of E-selectin ligands. Here, the authors  elaborate on how E-selectin and its ligands may facilitate leukocyte or tumor  cell recruitment in inflammatory and metastatic settings. Antagonists that target  cellular interactions with E-selectin and other members of the selectin family,  including neutralizing monoclonal antibodies, competitive ligand inhibitors or  metabolic carbohydrate mimetics, exemplify a growing arsenal of potentially  effective therapeutics in controlling inflammation and the metastatic behavior of  cancer.|*Drug Delivery Systems[MESH]|Animals[MESH]|Anti-Inflammatory Agents/administration & dosage[MESH]|Antineoplastic Agents/administration & dosage[MESH]|Cell Movement[MESH]|Humans[MESH]|Inflammation/*drug therapy/physiopathology[MESH]|Ligands[MESH]|Neoplasm Metastasis/drug therapy[MESH]|Neoplasms/*drug therapy/physiopathology[MESH]|Selectins/drug effects/*metabolism[MESH]
 |